Olodaterol

Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively) . Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis[1][2][3].

Product Specifications

CAS Number

[868049-49-4]

Product Name Alternative

BI1744

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Olodaterol.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic; warming)

Smiles

O=C1NC2=CC(O)=CC([C@@H](O)CNC(C)(C)CC3=CC=C(OC)C=C3)=C2OC1

Molecular Formula

C21H26N2O5

Molecular Weight

386.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Xing G, et al. Design, synthesis and biological evaluation of 8- (2-amino-1-hydroxyethyl) -6-hydroxy-1,4-benzoxazine-3 (4H) -one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2020;28 (1) :115178.|[2]Herrmann FE, et al. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol. 2017;174 (21) :3848-3864.|[3]Bouyssou T, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models [published correction appears in J Pharmacol Exp Ther. 2013 Jul;346 (1) :161]. J Pharmacol Exp Ther. 2010;334 (1) :53-62.